Merck’s Keytruda posts trial win in ‘messy’ early NSCLC realm – FiercePharma

by

  1. Merck’s Keytruda posts trial win in ‘messy’ early NSCLC realm FiercePharma
  2. PRO Outcomes With Dostarlimab/Chemotherapy Similar to Chemotherapy Alone in 3-Year Follow-Up of Patients With Endometrial Cancer OncLive
  3. Addition of Pembrolizumab to Chemotherapy Can Significantly Improve Survival Outcomes in Patients with Cervical Cancer Pharmacy Times
  4. Major Need Being Met: Imfinzi-Lynparza Combo Can Significantly Slow Progression of Ovarian Cancer Without BRCA Mutations, Study Suggests SurvivorNet
  5. KEYNOTE-671: EFS Benefit With Neoadjuvant Pembro Plus Chemo Followed by Resection and Adjuvant Pembro in Early-Stage NSCLC ASCO Daily News
  6. View Full Coverage on Google News

Read original article here

Leave a Comment